Abstract 1571
Background
Papillary carcinoma is the most common type of thyroid cancer and if it is not treated early, it can spread throughout the body. Therefore, the first line of treatment for papillary thyroid cancer is the surgery by removing part of or the entire thyroid. Our study aims to establish the most effective surgical procedure (total thyroidectomy or partial thyroidectomy) to achieve better survival for stage I and II papillary carcinoma and evaluate the effect of the ethnicity, sex and age on patients' survival undergoing these surgical techniques.
Methods
We extracted the data from the Surveillance, Epidemiology, and End Results (SEER) 18 registries. We retrieved data of 3691 patients diagnosed with papillary thyroid cancer in 2010. We evaluated the 5-year overall survival of patients using the log-rank test. Patients were grouped into two groups. The first one underwent thyroid lobectomy (242) and the second underwent total thyroidectomy (3449). Patients were further grouped according to ethnicity (white, black, American or Asian), sex (female or male) and age group.
Results
We found that total thyroidectomy was associated with better 5-year overall survival rates in patients with early stage papillary carcinoma, compared to lobectomy (98.1% and 96.5%, respectively, P = 0.021). Moreover, total thyroidectomy showed better survival rates in females than males (98.6% and 95.7%, respectively, p = 0.000) and in young patients aged between 20-39 years (99.8%, p = 0.000). Meanwhile, surgical techniques were not significantly associated with patients’ ethnicity.
Conclusions
Total thyroidectomy was superior to lobectomy in early stages papillary thyroid carcinoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sara Ahmed.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3608 - Prognostic impact of Body Mass Index (BMI) on overall survival in patients with metastatic breast cancer
Presenter: Khalil SALEH
Session: Poster Display session 2
Resources:
Abstract
2686 - Clinicopathological characteristics, survival and prognostic factors of breast cancer-related microangiopathic haemolytic anemia: a multicenter study
Presenter: Marion Alhenc Gelas
Session: Poster Display session 2
Resources:
Abstract
1565 - Metabolic tumor volume by 18F-FDG PET/CT is an independent prognostic factor in metastatic breast cancer
Presenter: Heekyung Ahn
Session: Poster Display session 2
Resources:
Abstract
4498 - Patient Preferences for breast cancer treatments: A Discrete Choice Experiment from four European countries
Presenter: Thomais Konstantopoulou
Session: Poster Display session 2
Resources:
Abstract
1423 - Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study
Presenter: Diana Lüftner
Session: Poster Display session 2
Resources:
Abstract
2284 - Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype
Presenter: Hee Kyung Kim
Session: Poster Display session 2
Resources:
Abstract
4598 - Administration of chemotherapy for metastatic breast cancer near the end of life: a population registry study
Presenter: Luisa Edman Kessler
Session: Poster Display session 2
Resources:
Abstract
5706 - Prognostic value of histological growth pattern in patients operated for breast cancer liver metastases
Presenter: Ali Bohlok
Session: Poster Display session 2
Resources:
Abstract
1697 - Illness perceptions, quality of life and mood in metastatic breast cancer patients
Presenter: Isabel Domingues
Session: Poster Display session 2
Resources:
Abstract
1935 - Multidisciplinary Treatments Increases Overall Survival in Patients with Newly Diagnosed Stage IV Breast Cancer:An Analysis of 2010–2014 SEER Data
Presenter: Jian Zhang
Session: Poster Display session 2
Resources:
Abstract